Oligonucleotide Therapeutics 101: Chemistry & Drug Delivery

Added:

RNA-Targeting Small Molecules: Overcoming the Delivery and Cost Barriers of Oligonucleotides

While oligonucleotide therapeutics (like siRNA and antisense oligonucleotides) offer precise gene targeting, they face severe biological limitations, particularly regarding delivery outside the liver, high manufacturing costs, and potential immunogenicity. A prominent alternative paradigm is the development of RNA-targeting small molecules. Unlike large, negatively charged oligonucleotides that require complex chemical modifications or lipid nanoparticles to enter cells, small molecules can be designed to selectively bind to complex three-dimensional RNA structures. This approach offers traditional pharmacological advantages, including oral bioavailability, superior tissue distribution (such as crossing the blood-brain barrier), and significantly lower production costs. Critics of the oligonucleotide-centric view argue that targeting RNA with small molecules represents a more scalable, accessible, and patient-friendly therapeutic strategy that bypasses the persistent delivery bottlenecks of nucleic acid-based drugs.

The Central Dogma of Molecular Biology: A solid understanding of DNA transcription, RNA translation, and how genetic information is expressed as proteins.
Basic Nucleic Acid Chemistry: Familiarity with the chemical structure of nucleotides, including phosphate backbones, ribose/deoxyribose sugars, nitrogenous bases, and Watson-Crick base-pairing principles.
Mechanisms of Gene Regulation: An introductory knowledge of endogenous cellular mechanisms for gene silencing, such as the RNA interference (RNAi) pathway and microRNAs.
Principles of Pharmacology and Drug Delivery: A foundational understanding of pharmacokinetics, biological barriers (like the cell membrane and endosomes), and the general challenges of delivering therapeutics to target tissues.
Next-Generation Chemical Modifications: In-depth study of advanced chemical strategies used to enhance oligonucleotide stability and binding affinity, such as Locked Nucleic Acids (LNAs) and Peptide Nucleic Acids (PNAs).
Targeted Delivery Vehicles: Exploration of advanced nanocarriers and conjugation technologies, such as Lipid Nanoparticles (LNPs) and GalNAc (N-acetylgalactosamine) conjugates for tissue-specific targeting.
Clinical Case Studies of Approved Therapeutics: Detailed analysis of the clinical trials, pharmacodynamics, and therapeutic outcomes of specific approved drugs like Patisiran (Onpattro) or Nusinersen (Spinraza).
Regulatory and Manufacturing Challenges: Investigation into the Chemistry, Manufacturing, and Controls (CMC) requirements, synthesis scale-up, and regulatory pathways specific to oligonucleotide-based drug development.
12.4K views96likes22:47@oligotherapeuticsOriginal Release: 2018-10-31

Oligonucleotide therapeutics represent a revolutionary class of drugs that target nucleic acids directly, offering new approaches to treat diseases by modulating gene expression through mechanisms such as antisense oligonucleotides (which recruit RNase H to degrade mRNA), siRNAs (which use the RNAi pathway for gene silencing), and splice-switching oligonucleotides (which correct genetic mutations by modulating pre-mRNA splicing). Key chemical modifications including phosphorothioate linkages (which provide metabolic stability and broad tissue distribution), 2'-O-methyl and methoxyethyl modifications (which enhance binding affinity and cellular uptake), and gapmer designs (which combine modified wings with unmodified central regions to activate RNase H) have been essential for overcoming the intrinsic challenges of oligonucleotides, including their high molecular weight, negative charges, hydrophilicity, and susceptibility to nucleases. Successful delivery to target tissues, particularly the liver, has been achieved through platforms like lipid nanoparticles and GalNAc conjugates, enabling six approved oligonucleotide therapeutics over the past 20 years.